Insider · SEC Form 4 filer
Gregory Lucier
Past buys: 2 of 8 beat
Companies
Where they file as an insider
Maravai Lifesciences (MRVI) Director Latest filing Jun 9, 2026
Dentsply Sirona (XRAY) Director Latest filing Jun 3, 2026
Avantor (AVTR) Director Latest filing May 8, 2026
Catalent (CTLT) Director Latest filing Dec 18, 2024
Bruker Cellular Analysis (CELL) Director Latest filing Oct 2, 2023
Track record
Did their buys beat the typical stock?
Open-market buys13
Quarters checked 6 months later8
Beat the typical stock 2 of 8
Quarters too new to check1
2 of 8 checked quarters beat the typical stock. A past record is data, not a forecast.
Avantor (AVTR) Bought May 8, 2026 · $83.2K · 10,000 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Dentsply Sirona (XRAY) Bought Mar 2–9, 2026 · $894K · 65,000 shares Behind typical Mar 31, 2026 $11.60 → Sep 30, 2026 $8.86 · −23.6% (typical stock +1.7%)
Avantor (AVTR) Bought Feb 19, 2026 · $458K · 50,000 shares Beat typical Mar 31, 2026 $7.84 → Sep 30, 2026 $15.05 · +92.0% (typical stock +1.7%)
Maravai Lifesciences (MRVI) Bought Dec 5–8, 2025 · $369K · 100,000 shares Beat typical Dec 31, 2025 $3.25 → Jun 30, 2026 $6.24 · +92.0% (typical stock +4.7%)
Dentsply Sirona (XRAY) Bought Mar 3, 2025 · $250K · 15,142 shares Behind typical Mar 31, 2025 $14.94 → Sep 30, 2025 $12.69 · −15.1% (typical stock +7.3%)
Dentsply Sirona (XRAY) Bought Nov 15–18, 2024 · $110K · 6,000 shares Behind typical Dec 31, 2024 $18.98 → Jun 30, 2025 $15.88 · −16.3% (typical stock −3.4%)
Dentsply Sirona (XRAY) Bought Aug 8, 2024 · $200K · 8,212 shares Behind typical Sep 30, 2024 $27.06 → Mar 31, 2025 $14.94 · −44.8% (typical stock −7.5%)
Dentsply Sirona (XRAY) Bought May 31, 2024 · $100K · 3,577 shares Behind typical Jun 30, 2024 $24.91 → Dec 31, 2024 $18.98 · −23.8% (typical stock +3.9%)
Dentsply Sirona (XRAY) Bought Nov 22, 2023 · $314K · 10,000 shares Behind typical Dec 31, 2023 $35.59 → Jun 30, 2024 $24.91 · −30.0% (typical stock −1.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.